National Institute on Drug Abuse; Notice of Closed Meetings, 5364-5366 [2023-01683]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
5364
Federal Register / Vol. 88, No. 18 / Friday, January 27, 2023 / Notices
Place: National Institutes of Health, Claude
D. Pepper Building, 6th Floor, C-Wing,
Conference Rooms F & G, 31 Center Drive,
Bethesda, MD 20892.
Closed: February 8, 2023, 11:30 a.m. to
4:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health, Claude
D. Pepper Building, 6th Floor, C-Wing,
Conference Rooms F & G, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: Tracy L. Waldeck, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Mental Health, NIH,
DHHS Neuroscience Center, 6001 Executive
Boulevard, Bethesda, MD 20892, (301) 480–
6833, tracy.waldeck@nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
conflicts.
Any member of the public interested in
presenting oral comments to the committee
must notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice at
least 10 days in advance of the meeting. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page:
www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: January 23, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01677 Filed 1–26–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:53 Jan 26, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; Clinical Trials
Review Study Section.
Date: March 2–3, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Keary A Cope, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209–A,
Bethesda, MD 20892–7924, (301) 827–7912,
copeka@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: January 23, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01674 Filed 1–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence Study
Section.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: January 23, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01675 Filed 1–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
E:\FR\FM\27JAN1.SGM
27JAN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 18 / Friday, January 27, 2023 / Notices
Support for Conferences and Scientific
Meetings.
Date: February 22, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Transformative Research on the Basic
Mechanisms of Polysubstance use in
Addiction.
Date: February 27, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
REI: Research on Neurocognitive
Mechanisms Underlying the Impact of
Structural Racism on the Substance Use
Trajectory.
Date: March 2, 2023.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Brian Stefan Wolff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 480–1448,
brian.wolff@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Accelerating the Pace of Drug Abuse
Research Using Existing Data.
Date: March 3, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Li Rebekah Feng, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
VerDate Sep<11>2014
16:53 Jan 26, 2023
Jkt 259001
6021, Bethesda, MD 20892, (301) 827–7245,
rebekah.feng@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Centers Grant Program (P50) (P30).
Date: March 3, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jenny Raye Browning,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
jenny.browning@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Centers Grant Program (P50) (P30).
Date: March 6–7, 2023.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Scientific Review,
Branch Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Therapeutic Development of
Psychoplastogenic Compounds for Substance
Use Disorders.
Date: March 7, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Brian Stefan Wolff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 480–1448,
brian.wolff@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; DeviceBased Treatments for Substance Use
Disorders.
Date: March 8, 2023.
Time: 11:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
nayarp2@csr.nih.gov.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
5365
Name of Committee: National Institute on
Drug Abuse Initial Review Group; Career
Development Education and Training Study
Section.
Date: March 9, 2023.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Chemical Countermeasures Research
Program (CCRP) Initiative: Basic Research on
The Deleterious Effects of Acute Exposure to
Ultra-Potent Synthetic (UPS) Opioids.
Date: March 9, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Li Rebekah Feng, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 827–7245,
rebekah.feng@nih.gov.
Name of Committee: National Institute on
Drug Abuse Initial Review Group;
Medication Development Research Study
Section.
Date: March 15, 2023.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, 301–443–4577,
nayarp2@csr.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
REI: Racial Equity Visionary Award Program
for Research on Substance Use and Racial
Equity.
Date: March 16–17, 2023.
Time: 9:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
E:\FR\FM\27JAN1.SGM
27JAN1
5366
Federal Register / Vol. 88, No. 18 / Friday, January 27, 2023 / Notices
Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 23, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01683 Filed 1–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
[Document Identifier: 0930–0092]
Agency Information Collection
Request; 30-Day Public Comment
Request
Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
SUPPLEMENTARY INFORMATION:
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Confidentiality
of Substance Use Disorder Patient
Records, 42 CFR part 2.
Type of Collection: Extension.
OMB No. 0930–0092.
Abstract: The Substance Abuse and
Mental Health Services Administration
(SAMHSA) requests approval to extend
this existing, approved collection
without changing any collecting
requirements. HHS also expects to
obtain public comment through a Notice
of Proposed Rulemaking (NPRM), which
proposes modifications to 42 CFR part
2 that would affect the hourly burdens
associated with the regulations. 87 FR
74216 (December 2, 2022). At the final
rule stage, the Department intends to
replace this existing, approved
collection with an updated information
collection reflecting changes in the rule
and updated wage rates and regulated
entity statistics.
Likely Respondents: Part 2 programs,
qualified service organizations, patients
with substance use disorders, and
professional and trade associations of
SUD treatment providers.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Department
of Health and Human Services,
Substance Abuse and Mental Health
Services Administration is publishing
the following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before February 27, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT:
Carlos.Graham@samhsa.hhs.gov or call
(240) 276–0361. When submitting
comments or requesting information,
please include the document identifier
0930–0092 and project title for
reference.
SUMMARY:
ESTIMATED ANNUALIZED BURDEN TABLE 1
Part 2 provision
Annual number
respondents
(SUD
programs)
Responses per
respondent
Total
responses
(treatment
admissions)
Average
burden per
response
Total burden
hours
Average cost
per response
Total hourly
cost
DISCLOSURES
2.22 ..........................
2.31, 2.52, 2.53 elec.
& paper disclosures .....................
13,585
122.10
1,658,729
0.20
331,746
$9.60
$15,923,798
13,585
18.31
248,741
0.62
155,463
28.00
6,964,748
RECORDKEEPING
2.36 ..........................
2.51 ..........................
13,585
13,585
195.80
2.00
2,659,943
27,170
0.033
0.167
87,778
4,537
1.60
7.47
4,255,909
202,960
Total ..................
..........................
..........................
4,594,583
........................
579,524
........................
27,347,415
1 The
khammond on DSKJM1Z7X2PROD with NOTICES
burden table reflects entries approved for the current ICR based on calculating the average cost per response and contains changes to
the table published in the 60-day FEDERAL REGISTER Notice. See 87 FR 71341 (November 22, 2022), 87 FR 75058 (December 7, 2022) (correction issued), and 87 FR 76634 (December 15, 2022) (correction issued).
Carlos Graham,
PRA Reports Clearance Officer.
[FR Doc. 2023–01657 Filed 1–26–23; 8:45 am]
BILLING CODE 4162–20–P
VerDate Sep<11>2014
16:53 Jan 26, 2023
Jkt 259001
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
E:\FR\FM\27JAN1.SGM
27JAN1
]]>Agencies
[Federal Register Volume 88, Number 18 (Friday, January 27, 2023)]
[Notices]
[Pages 5364-5366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01683]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH
[[Page 5365]]
Support for Conferences and Scientific Meetings.
Date: February 22, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 827-4471,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Transformative Research on the Basic Mechanisms of
Polysubstance use in Addiction.
Date: February 27, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA REI: Research on Neurocognitive Mechanisms
Underlying the Impact of Structural Racism on the Substance Use
Trajectory.
Date: March 2, 2023.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 480-1448, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Accelerating the Pace of Drug Abuse Research Using
Existing Data.
Date: March 3, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Li Rebekah Feng, Ph.D., Scientific Review
Officer, Scientific Review Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827-7245, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Centers Grant Program (P50) (P30).
Date: March 3, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jenny Raye Browning, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Centers Grant Program (P50) (P30).
Date: March 6-7, 2023.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Scientific Review, Branch Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Therapeutic Development of Psychoplastogenic
Compounds for Substance Use Disorders.
Date: March 7, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 480-1448, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Device-Based Treatments for Substance Use Disorders.
Date: March 8, 2023.
Time: 11:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-
4577, [email protected].
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Career Development Education and Training Study
Section.
Date: March 9, 2023.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Chemical Countermeasures Research Program (CCRP)
Initiative: Basic Research on The Deleterious Effects of Acute
Exposure to Ultra-Potent Synthetic (UPS) Opioids.
Date: March 9, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Li Rebekah Feng, Ph.D., Scientific Review
Officer, Scientific Review Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827-7245, [email protected].
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Medication Development Research Study Section.
Date: March 15, 2023.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301-443-
4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA REI: Racial Equity Visionary Award Program for
Research on Substance Use and Racial Equity.
Date: March 16-17, 2023.
Time: 9:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021,
[[Page 5366]]
Bethesda, MD 20892, (301) 496-9350, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 23, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-01683 Filed 1-26-23; 8:45 am]
BILLING CODE 4140-01-P
